华兰生物：帕博利珠单抗注射液获准开展临床试验

Core Viewpoint - Hualan Biological (002007.SZ) announced that its associate company, Hualan Ankang Biological Co., Ltd., received the Clinical Trial Approval Notification from the National Medical Products Administration for the clinical trial of Pembrolizumab injection as a biosimilar [1] Group 1: Company Developments - Hualan Ankang has been granted approval to conduct clinical trials for Pembrolizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) [1] - The approval signifies a strategic move for Hualan Biological in the oncology sector, particularly in the development of immunotherapy drugs [1] Group 2: Industry Insights - Pembrolizumab functions by blocking the interaction between PD-1 and its ligands PD-L1/PD-L2, thereby restoring T cell anti-tumor activity and enhancing the immune system's ability to combat tumors [1] - As an immune checkpoint inhibitor, Pembrolizumab has become a standard treatment option for various advanced malignancies, revolutionizing the landscape of cancer treatment [1]